Recent

% | $
Quotes you view appear here for quick access.

Facebook, Inc. (FB) Message Board

buster55391 4130 posts  |  Last Activity: Apr 15, 2015 10:10 AM Member since: Oct 11, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • buster55391 by buster55391 Apr 15, 2015 10:10 AM Flag

    spread has tightened up.033/.0338
    Maybe it is time to go - TO THE MOON!

  • buster55391 by buster55391 Apr 10, 2015 1:21 PM Flag

    but know actual trades ?
    Probably because of our penny stock status...

  • buster55391 by buster55391 Apr 10, 2015 1:11 PM Flag

    this stock has continued it's upward angle at a very aggressive incline. Where will it stop. really?
    Just look at the chart.

  • buster55391 by buster55391 Apr 10, 2015 12:52 PM Flag

    CNBC bashing this is reason enough for me to buy more.

    Product placement amongst our pop culture will be significant DRIVING sales of the watch to numbers NO body expected. Except maybe SJ - rest in peace brother.

    And, additionally this watch will drive Twitter and FB to higher new levels. watch.

  • buster55391 by buster55391 Apr 6, 2015 11:47 AM Flag

    lets go.

  • buster55391 by buster55391 Apr 2, 2015 10:55 AM Flag

    it "appears" we have settled in at this .03 spot, as our new low.
    Steady slow up from here. TOO THE MOON!

  • buster55391 by buster55391 Mar 30, 2015 10:18 AM Flag

    at .032 with 377,000 shares sitting on it. Could be a busy day.
    Or maybe not...

  • buster55391 buster55391 Mar 27, 2015 1:02 PM Flag

    "Medtronics of the world banging on your door. "

    wouldn't that be nice.

  • buster55391 buster55391 Mar 27, 2015 10:43 AM Flag

    Looks like they released what I found. Good. It IS good news. Gives some "evidence" to the positive attributes of the product and leads into some new territories potentially. China would be huge. Surprised that word alone did not bump us up even more.
    I will take .03 over .01 for now and continue to hope that what are finally starting to see will manifest itself into some actual business and astronomical growth.

    I spoke with a close friend, who is a financial advisor, he is buying heavily in the healthcare sector currently. And that is the recommendation to their clients as well. Did not mention SCIE to him as ETFs are their focus. But confirmation of the healthcare sector being a large part of their focus is reassuring for us when we finally get some traction.

    If the PR is solid and what was printed comes to fruition, this will explode. It will.
    BUT ...

  • Reply to

    China

    by buster55391 Mar 20, 2015 1:08 PM
    buster55391 buster55391 Mar 20, 2015 3:16 PM Flag

    Quite- enough to know that if they do "make it" it won't work - very well...

  • buster55391 by buster55391 Mar 20, 2015 1:08 PM Flag

    "Pursue the introduction of the WavSTAT4 colon cancer application in other international markets, in particular China, Saudi Arabia and India;"

    Everybody wants China. If we can actually "get in to China" .025 will have a massive decimal shift in our favor.

  • buster55391 buster55391 Mar 19, 2015 5:07 PM Flag

    I like that part - wondering why a Press Release has not been released with this in it...

  • A low-intensity and non-damaging laser light is directed from the WavSTAT4® mobile console through an optical fibre mounted in the single use WavSTAT4® optical biopsy forceps. These are directed through the working channel of the colonoscope (a standard endoscope) and brought into direct contact with the polyp. The polyp tissue absorbs the laser light, resulting in the excitation of the tissue being examined. The resulting autofluorescent signal is sent back and analysed by a waveform analysis algorithm in the console, to diagnose precancerous colon polyps. A green ‘non-suspect’ or a red ‘suspect’ result is displayed on the console's screen within seconds. A biopsy sample can be taken using the forceps. WavSTAT4® is CE marked and is currently in use at St James University Hospital in Leeds, as part of a European trial. A full commercial launch in the UK is expected in Q2 2015. WavSTAT® has been developed through the National Institute for Health Research (NIHR) Colorectal Therapies Healthcare Technology Co-operative (HTC). The HTC engages industry, NHS, scientists, charities, engineers, patients and public in identifying areas within colorectal therapies where development of new technology would be of benefit to patients.

  • Reply to

    PAY DIRT

    by buster55391 Mar 18, 2015 3:34 PM
    buster55391 buster55391 Mar 18, 2015 6:23 PM Flag

    thus, part of the problem with not getting any updates direct from the co.
    I just dug around a bit and found some if this stuff. Last time a dug around I did not find this - that was late last year - so it would appear to me, without anything other what I saw today, that things are happening. What will become of it. Hopefully what the few of us still here have been waiting for, of far too long.

  • Reply to

    PAY DIRT

    by buster55391 Mar 18, 2015 3:34 PM
    buster55391 buster55391 Mar 18, 2015 3:35 PM Flag

    maybe not this actually does not sound good - AT ALL.

    2015 Jan;47(1):56-62. doi: 10.1055/s-0034-1378112. Epub 2014 Sep 29.
    Automatic optical diagnosis of small colorectal lesions by laser-induced autofluorescence.
    Kuiper T1, Alderlieste YA1, Tytgat KM1, Vlug MS1, Nabuurs JA1, Bastiaansen BA1, Löwenberg M1, Fockens P1, Dekker E1.
    Author information
    Abstract
    BACKGROUND AND STUDY AIMS:
    Endoscopic optical diagnosis can potentially replace histopathological evaluation of small colorectal lesions. The aim of this study was to evaluate diagnostic performance of WavSTAT, a novel system for automatic optical diagnosis based on laser-induced autofluorescence spectroscopy.
    PATIENTS AND METHODS:
    Consecutive patients who were scheduled for colonoscopy were included in the study. Each detected lesion with a size of ≤ 9 mm was differentiated using high resolution endoscopy (HRE) by the endoscopist, who then reported this as a low or high confidence call. Thereafter, all lesions were analyzed using WavSTAT. Histopathology was used as the reference standard. The primary outcome measures were the accuracy of WavSTAT to differentiate between adenomatous and nonadenomatous lesions, and the accuracy of an algorithm combining HRE (lesions differentiated with high confidence) and WavSTAT (all remaining lesions). The secondary outcome measure was the accuracy of on-site recommended surveillance intervals.
    RESULTS:
    At total of 87 patients with 207 small colorectal lesions were evaluated. Accuracy and negative predictive value of WavSTAT were 74.4 % and 73.5 %, respectively. The corresponding figures for the algorithm were 79.2 % and 73.9 %, respectively. Accuracy of on-site recommended surveillance interval was 73.7 % for WavSTAT alone and 77.2 % for the algorithm of HRE and WavSTAT.
    CONCLUSIONS:
    Both accuracy of WavSTAT alone and the algorithm combining HRE with WavSTAT proved to be insufficient for the in vivo differentiation of small colorectal lesions, and do not fulfill American Socie

  • buster55391 by buster55391 Mar 18, 2015 3:34 PM Flag

    Photodiagnosis Photodyn Ther. 2015 Mar;12(1):76-83. doi: 10.1016/j.pdpdt.2014.12.003. Epub 2015 Jan 3.
    Laser-induced autofluorescence spectroscopy: Can it be of importance in detection of bladder lesions?
    Aboumarzouk O1, Valentine R2, Buist R2, Ahmad S3, Nabi G4, Eljamel S5, Moseley H2, Kata SG3.
    Author information
    Abstract
    BACKGROUND:
    Non-muscle invasive bladder cancer can be missed during white light endoscopy in up to 50% of cases. We aimed to test whether or not we could find a difference between benign and cancerous tissue wavelengths using laser induced autofluorescence spectroscopy can increase cancer detection.
    MATERIALS AND METHODS:
    We analysed 67 tissue samples using spectral analysis. The WavSTAT (Spectra Science) optical biopsy device was used to record fluorescence spectra from biopsied tissue enabling calculation of an AUC for each spectrum, a measure of the mean spectral wavelength (λ¯ (nm)) and a dimensionless fluorescence ratio. Mann-Whitney test was used to compare the two groups.
    RESULTS:
    We found that 49.3% (33/67) of the tissue was benign, 44.8% (30/67) was CIS/cancerous tissue, and the remaining 4/67 samples were atypia (2) and dysplasia (2). The median AUC for the benign tissue was 19.53 (interquartile range [IQR]: 5.35-30.39) and that for CIS/cancerous tissue was 7.05 (IQR: 2.89-14.24) (P=0.002). The median wavelengths for the benign tissue and malignant tissue were 502.4nm (IQR: 500.3-504.3nm) and 505.2nm (IQR: 502.1-513.2nm), respectively (P=0.003). The median fluorescence ratio was 0.080 (IQR: 0.070-0.088) for benign tissue and 0.096 (IQR: 0.079-0.221) for CIS/cancerous tissue (P=0.002).
    CONCLUSIONS:
    We found statistical differences between the median AUC calculations and median wavelengths for the benign and cancerous tissue. We also found a statistical difference between the fluorescence ratios between the two tissue types. There seems to be a role for optical spectroscopy in verifying bladder lesions.
    Copyright © 2014 Elsevier B.V. All

  • buster55391 by buster55391 Mar 18, 2015 3:29 PM Flag

    a bit today it appears we are in the midst of testing and should know something by May this year. It seems there are 152 participants in our study. It would be great of someone else here could dig into what I have provided to confirm or see if you find something additional. I think this seems to be potentially really good news - the facts that testing is actually underway, and would should know something in May. I hope what I found is accurate - it seems to be...

  • buster55391 by buster55391 Mar 18, 2015 3:24 PM Flag

    clinicaltrials.gov/ct2/show/study/NCT02138318

  • Estimated Enrollment: 152
    Study Start Date: May 2012
    Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)

  • Reply to

    View of NCT02138318 on 2014_05_13

    by buster55391 Mar 18, 2015 3:17 PM
    buster55391 buster55391 Mar 18, 2015 3:18 PM Flag

    Descriptive Information
    Brief title
    High Definition Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis (UC)

    Official title
    Randomized Controlled Trial of High Definition White Light Endoscopy Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis Surveillance

    Brief summary
    Patients with ulcerative colitis (UC) have an increased risk for colorectal cancer (CRC) compared to the general population. Regular screening by colonoscopy is an internationally recommended cancer prevention strategy. Random sampling of the mucosa throughout the colon has been the mainstay of conventional surveillance practice to detect abnormalities, known as dysplasia which can progress to CRC. This requires multiple biopsies, to be taken and processed, a practice which is is tedious, expensive, time consuming and has a low pickup rate. Dysplasia in UC is
    typically flat and patchy and can be easily overlooked with standard conventional white light colonoscopy (WLC).
    Detection can be improved by the application of dyes which highlight more subtle abnormalities. This practice, known as chromoendoscopy (CE) is better than WLC at dysplasia detection but more time consuming for the patient and cannot guarantee that the whole colon is covered. CE has only been compared in clinical trials with standard definition endoscopy rather than the recently available high definition endoscopes with better resolution and picture. High definition (HD) endoscopy uses a high definition onitor and a high resolution CCD (charge coupled device) providing much better images than standard video endoscopy. HD colonoscopy promises therefore to provide an alternative to CE in UC surveillance without the need for the extra time and experience required for dye spraying for both endoscopists and nursing staff.
    The investigators plan to do a randomized trial to assess HD colonoscopy alone compared to chromoendoscopy (with HD colonoscopies) for dysplasia detection during surveillance for ulc

FB
80.775-1.5350(-1.86%)Apr 17 4:00 PMEDT